ScholarLens Back to search
2001•Chinese Journal of New Drugs and Clinical RemediesRequires access

Acarbose vs metformin in treating non insulin dependent diabetes mellitus

Feng Ji

Open publisher page 0 citations

Abstract

AIM: To compare the efficacy of acarbose and metformin in treating non insulin dependent diabetes mellitus (NIDDM). METHODS: Sixty patients with NIDDM were divided into two groups. Thirty patients (M15, F15; age 61 a± s 13 a) were treated with acarbose 50-100 mg po , tid×6 wk; and after 30 patients (M16, F14; age 60±12 a) with metformin 250-500 mg, po , tid×6 wk as control. RESULTS: The fasting and 2 h postprandial blood glucose were remarkably lowered after therapy by acarbose and metformin. The effective rate of acarbose were 83 % and 97 %; and the effective rate of metformin were 87 % and 73 %. Acarbose was superior to metformin (in reducing 2 h postprandial blood glucose, P 0.01). And acarbose aws worse than metformin in lowering total cholesterol (TC)( P 0.01). The rates of adverse reaction were respectively 17 % and 11 %. CONCLUSION: Acarbose is a safe and effective drug in the treatment of NIDDM.

About this research paper

What this paper is about

AIM: To compare the efficacy of acarbose and metformin in treating non insulin dependent diabetes mellitus (NIDDM). METHODS: Sixty patients with NIDDM were divided into two groups. Thirty patients (M15, F15; age 61 a± s 13 a) were treated with acarbose 50-100 mg po , tid×6 wk; and after 30 patients (M16, F14; age 60±12 a) with metformin 250-500 mg, po , tid×6 wk as control. RESULTS: The fasting and 2 h postprandial blood glucose were remarkably lowered after therapy by acarbose and metformin. The effective rate of acarbose were 83 % and 97 %; and the effective rate of metformin were 87 % and 73 %. Acarbose was superior to metformin (in reducing 2 h postprandial blood glucose, P 0.01). And acarbose aws worse than metformin in lowering total cholesterol (TC)( P 0.01). The rates of adverse reaction were respectively 17 % and 11 %. CONCLUSION: Acarbose is a safe and effective drug in the treatment of NIDDM.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

AIM: To compare the efficacy of acarbose and metformin in treating non insulin dependent diabetes mellitus (NIDDM). METHODS: Sixty patients with NIDDM were divided into two groups. Thirty patients (M15, F15; age 61 a± s 13 a) were treated with acarbose 50-100 mg po , tid×6 wk; and after 30 patients (M16, F14; age 60±12 a) with metformin 250-500 mg, po , tid×6 wk as control. RESULTS: The fasting and 2 h postprandial blood glucose were remarkably lowered after therapy by acarbose and metformin. The effective rate of acarbose were 83 % and 97 %; and the effective rate of metformin were 87 % and 73 %. Acarbose was superior to metformin (in reducing 2 h postprandial blood glucose, P 0.01). And acarbose aws worse than metformin in lowering total cholesterol (TC)( P 0.01). The rates of adverse reaction were respectively 17 % and 11 %. CONCLUSION: Acarbose is a safe and effective drug in the treatment of NIDDM.

Key concepts: Acarbose, Postprandial, Metformin, Medicine, Internal medicine, Diabetes mellitus, Endocrinology, Insulin

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Acarbose vs metformin in treating non insulin dependent diabetes mellitus — Research Paper | ScholarLens